Early access to medicines scheme (EAMS) scientific opinion: sacubitril/valsartan
Information on the EAMS scientific opinion given to sacubitril/valsartan, including the public assessment report.
Documents
Details
This positive scientific opinion was issued to Novartis for sacubitril/valsartan, to reduce the risk of cardiovascular mortality and morbidity in adult patients with symptomatic heart failure and reduced ejection fraction.
The scientific opinion includes:
- a public assessment report
- a treatment protocol:
- for healthcare professionals
- for patients
- on the pharmacovigilance system
Contact
Information and details regarding patient access
Heart failure specialists wishing to access this EAMS medicine in England can submit a request to medinfo.uk@novartis.com to register a patient.
For information about access in Northern Ireland, contact Mark Timoney, Chief Pharmaceutical Officer at Mark.Timoney@dhsspsni.gsi.gov.uk and Joe Magee, Secondary Care Directorate at Joe.Magee@dhsspsni.gov.uk.
For information about access in Scotland contact the Scottish Government Directorate General Health & Social Care. Please email John.Hannah@scotland.gsi.gov.uk and Kathryn.Fergusson@scotland.gsi.gov.uk.
For information about access in Wales, contact the Welsh Government Department of Health and Social Services by e-mailing Roger Walker Chief Pharmaceutical Officer at Roger.Walker@wales.gsi.gov.uk and Karen Eveleigh, Head of Pharmacy & Prescribing policy at Karen.Eveleigh@wales.gsi.gov.uk.